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Introduction
The goal of ‘Ending the AIDS epidemic as a public health threat by 2030’ has been reflected in
the Sustainable Development Goals (SDGs), and similar language has been adapted for other
diseases and conditions [1]. Between 2010 and 2017, the number of AIDS-related deaths has
declined by 34%, and the number of new HIV infections has declined by 18% [2]. Although
these declines constitute important achievements, progress has been slower than envisaged,
which is likely due to a combination of suboptimal or inappropriate policies, lack of funding,
limited or misdirected implementation of available strategies and tools, or other obstacles.
Metrics and corresponding target values or benchmarks that demonstrate progress in the
AIDS response and its effect on the AIDS epidemic are useful as the world heads towards that
goal.
‘Ending the AIDS epidemic’ has not been defined in scientific terms, and it can be seen as a
global aspiration in a distant future. Elimination of all new infections does not appear possible
in the short and medium term with the tools available today. Metrics that signal medium-term
progress and can be applied in countries, subnational entities, and population groups may be
particularly valuable, as they can allow for local accountability and target-driven programme
management. Achieving a certain benchmark would then herald the gradual reduction in the
HIV burden in that community and could help lay the groundwork for a push to end the epi-
demic. The benchmarks for the metrics discussed in this paper should not be seen as indicative
of tipping points, as those are unlikely to exist in the real world for an infection with a long
incubation period and with survival being extended by antiretroviral treatment. Rather, they
can be seen as important achievements in the management of epidemics.
Metrics for tracking progress towards the end of the epidemic as a public health threat
should relate to both technical and popular interpretations of the concept of a ‘public health
threat’. HIV threatens affected populations in several ways. First, and most importantly, HIV
causes sickness and death, which together contribute to a country’s burden of disease. Second,
people living with HIV (PLHIV) and key populations at high risk of infection may be stigma-
tised, which may constitute an obstacle to effective implementation and warrants ongoing
monitoring. Third, the epidemic reduces the size and the productivity of a country’s work
force, imposing an indirect economic burden on the affected country. Finally, managing HIV
demands health spending by patients, governments, private insurers, and funders, and, in the
worst-affected lower-income countries, this fiscal burden can exceed all other health spending,
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with part of the cost borne by donor countries. Ending the epidemic as a public health threat
depends on reducing mortality and incidence by expanding treatment and prevention
services.
Here we discuss various HIV epidemic transition metrics that can be used to measure prog-
ress in reducing the public health threat of HIV, based on discussions at a meeting convened
by UNAIDS in October 2017 in Glion, Switzerland. These metrics have since been included in
UNAIDS’ 2018 reports [2,3] for countries and regions. Metrics and benchmarks to track prog-
ress in reducing stigma and discrimination—a goal to be pursued on its own merit that also
represents a reduction in key determinants of HIV-related service delivery—are also needed
and are discussed in a separate paper in preparation for this collection. Relevant and available
data for metrics to track progress in reducing stigma and discrimination have also been
included in UNAIDS’ 2018 reports [2,3].
HIV epidemic transition metrics
We consider six metrics: (1) an absolute rate of HIV incidence, (2) an absolute rate of AIDS-
related deaths, (3) a percentage reduction in new HIV infections, (4) a percentage reduction in
AIDS-related deaths [both 3 and 4 as compared to an agreed baseline date], (5) an incidence:
prevalence ratio (IPR), and (6) an incidence:mortality ratio (IMR). Fig 1 shows the changing
values of the six metrics globally for the percentage reduction during 2010–2016 and for the
other metrics during 1990–2016, based on UNAIDS estimates. Key characteristics of the met-
rics and their benchmark values are shown in Table 1.
An absolute rate of HIV incidence
The SDG target for HIV (indicator 3.3.1) is monitored by the number of new HIV infections
per 1,000 uninfected population, disaggregated by sex, age, and key populations [10]. A
Fig 1. Metrics for HIV transition, globally 1990–2020.
https://doi.org/10.1371/journal.pmed.1002678.g001
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Table 1. Key characteristics of proposed HIV epidemic transition metrics and their benchmark values.
HIV incidence rate AIDS-related
mortality rate
HIV incidence
reduction compared to
2010: 75% by 2020 and
90% by 2030
AIDS-related
mortality reduction
compared to 2010: 75%
by 2020 and 90% by
2030
Ratio of new HIV
infections over PLHIV
(IPR)
Ratio of new HIV
infections over all-
cause mortality
among PLHIV (IMR)
Benchmark value To be set locally To be set locally 75% by 2020
90% by 2030
75% by 2020
90% by 2030
0.03 1
Complexity Simple: a single rate
in a given year,
although the target
will need to be
setting specific.
Simple: a single rate
in a given year,
although the target
will need to be
setting specific.
Intermediate:
comparison of two
numbers
Intermediate:
comparison of two
numbers
Complex: ratio
between two quantities
Complex: ratio
between two quantities
(and requires an
ancillary condition
regarding low
mortality)
Use Adopted as main
indicator for
monitoring SDG
3.3.1.
Regularly used by
countries and
organisations.
Regularly used by
countries and
organisations.
Many countries have
adopted national
targets for 2020.
Few countries have
adopted national
targets.
Few countries have
used [4–9].
PEPFAR has proposed
in its strategies [22,23].
Relevance for
countries
Metric applies to all
countries, but
benchmark value
changes relative to
the level of
countries’ incidence
rate.
Metric applies to all
countries, but
benchmark value
changes relative to
the level of
countries’ AIDS-
related mortality
rate.
Applies to all countries,
regardless of number
of new infections in
2010.
Applies to all countries,
regardless of number of
AIDS-related deaths in
2010.
Applies to epidemics
of all sizes, regardless
of the level of
incidence or
prevalence.
Applies to epidemics
of all sizes, regardless
of the level of
incidence or mortality.
Rooted in
epidemiological
theory about the
sustainability of
transmission?
No—but the
threshold can be
setting specific and
chosen according to
empirical evidence
on HIV incidence
rates.
No—but the
threshold can be
setting specific and
chosen according to
empirical evidence
on AIDS death rates.
Partially.
The targets are derived
using a model that
represents the potential
impact on the epidemic
of a suite of
interventions.
Partially.
The targets are derived
using a model that
represents the potential
impact on the epidemic
of a suite of
interventions.
Yes Yes
Impact of target
achievement on
burdens:
a. Sickness, death
b. Fiscal burden
a. Eventually
reduces
b. Eventually
reduces
a. Immediately
reduces
b. Eventually
reduces
a. Eventually reduces
b. Eventually reduces
a. Immediately reduces
b. Eventually reduces
a. Eventually reduces
b. Reduces when
incidence is lower than
all-cause mortality
among HIV+ people
a. Immediately
reduces�
b. Immediately
reduces�
Other No universal
benchmark values
exist, as they will
change from
country to country
and by population
subgroups.
No universal
benchmark values
exist, as they will
change from
country to country
and by population
subgroups.
A 90% reduction in
incidence in one place
by 2030 could leave
incidence at a higher
incidence than
somewhere else in 2010
—i.e., the metric is
permissive to global
heterogeneity in
epidemic levels.
A 90% reduction in
AIDS-related mortality
in one place by 2030
could leave AIDS-
related mortality at a
higher level than
somewhere else in 2010
—i.e., the metric is
permissive to global
heterogeneity in
epidemic levels.
Applies to national or
regional populations,
not to subgroups of
the population for
which HIV
transmission occurs
between the groups,
notably sex- and age-
defined groups, and to
varying degrees key
population groups,
including sex workers,
transgender people,
men who have sex
with men, and people
who inject drugs.
Applies to national or
regional populations,
not to subgroups of
the population for
which HIV
transmission occurs
between the groups,
notably sex- and age-
defined groups, and to
varying degrees key
population groups,
including sex workers,
transgender people,
men who have sex
with men, and people
who inject drugs.
� When associated with an important reduction in mortality as discussed in the text.
Abbreviations: IMR, incidence:mortality ratio; IPR, incidence:prevalence ratio; PEPFAR, President’s Emergency Plan for AIDS Relief; PLHIV, people living with HIV;
SDG, Sustainable Development Goal.
https://doi.org/10.1371/journal.pmed.1002678.t001
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numerical target signifying the ‘End of the AIDS epidemic’ for the HIV incidence rate has
been proposed at 1/1,000 person-years (py) in South Africa in the original analysis exploring
the powerful effects of antiretroviral treatment in reducing incidence [11]. More recently, the
same target value of 1/1,000 py has also been suggested for other high-burden countries
[12,13].
However, incidence rates are very different in different populations. A target incidence
level for a country with high historical incidence, such as the countries in southern Africa, may
not be relevant for a country with historically lower incidence. For example, the incidence in
India, taken as a whole, was estimated to be 0.10 (0.08−0.14) / 1,000 py in 2016 [14], and it has
never exceeded the 1/1,000 py proposed benchmark [15]. Hence, meaningful targets can only
be set in countries and local jurisdictions.
While an incidence rate has been proposed for monitoring the SDG target, both the inci-
dence rate and the number of new HIV infections can be monitored. It is important to realise
that, in circumstances of important population growth, absolute numbers of new HIV infec-
tions could be increasing while the incidence rate is declining.
An absolute rate of AIDS-related deaths
The level of AIDS-related mortality varies among countries, within countries, by age, and by
population groups. AIDS-related mortality in South Africa, for example, peaked in 2006 when
42% of all deaths were attributable to HIV and the AIDS-related mortality rate was approxi-
mately 5/1,000 population [14,16,17]. While an AIDS-related mortality of less than 1/1,000 per
year may be relevant for the high-prevalence countries in southern Africa, meaningful targets
can only be set in countries and local jurisdictions. The proposed indicator for monitoring
AIDS-related mortality is the number of AIDS-related deaths per 1,000 population. As above
for the incidence metric, both the AIDS-related mortality rate and the number of AIDS-related
deaths can be monitored. In the case of important population growth and a decline in mortal-
ity, the rate would decline faster than the number of AIDS-related deaths.
A percentage reduction in the number of new HIV infections
For the purpose of the Fast-Track modelling, which aimed to develop programmatic targets
and resource needs estimates [18], ‘Ending the AIDS epidemic as a public health threat’ was
interpreted as achieving an important reduction in incidence and mortality. Programmatic
targets and effect estimates were included in the model for testing, treatment, and viral sup-
pression; condom use; key populations (men who have sex with men, sex workers, people who
inject drugs, transgender people, and prisoners) intervention packages; preexposure prophy-
laxis; voluntary male medical circumcision; and conditional cash transfers. Specifically, the
percentage reduction target was set to a 90% reduction in the number of new HIV infections
in the entire population between 2010 and 2030. The modelling of the impact resulting from
reaching the different programmatic targets achieved a reduction by 2030 of nearly 90% [18].
The 2016 UN high-level meeting adopted values of 90% reduction by 2030 and the interim tar-
get of 75% for the year 2020, as well as the corresponding programmatic target values [19].
A percentage reduction in the number of AIDS-related deaths
As for the above percentage reduction in new HIV infections, a 90% reduction in AIDS-related
deaths was aimed for in the Fast-Track modelling between 2010 and 2030 [18]. The modelling
of the impact resulting from reaching the different programmatic targets achieved a nearly
80% reduction by 2030 [18]. The 2016 UN high-level meeting adopted a target of 90%
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reduction by 2030 and 75% by 2020 for AIDS-related mortality, together with the correspond-
ing programmatic target values [19].
An IPR
The IPR (incidence:prevalence ratio) is defined as the number of new infections occurring per
year in a population divided by the number of persons living with HIV in that same popula-
tion. When the IPR is below a certain threshold, the epidemic declines—if the IPR is held
below that threshold for a long time, the epidemic will eventually be eliminated. The IPR is
thus an indicator for the epidemic response ‘proceeding in the right way’, as opposed to it hav-
ing achieved its goal of ending the AIDS epidemic. It was initially used by researchers in high-
income countries [20,4,5], relating it to the effective epidemic number and using it to judge
progress in the epidemic and the response. More recently, it has been used to judge progress in
the response to the United States epidemic [5–7].
A global benchmark value is obtained by considering the replacement level for the infec-
tion: for an epidemic to decline, on average, there should be fewer than one new infection per
person living with HIV over the course of their infection. If we assume that newly infected per-
sons survive for D years and there is an equal risk of transmission over this time and that it is
the same for all people, then it follows that the benchmark value is equal to 1/D at equilibrium.
Making further simplifying assumptions, we can say that D is approximately 33 years (the
approximate survival time, accounting for the proportion of PLHIV that benefit from antire-
troviral therapy [ART] under UNAIDS’ treatment targets) [9], and so the threshold may be
approximately 0.03. We note that this provides only a rough ‘rule of thumb’; a separate paper
is in preparation for this collection to explore further the behaviour of the IPR. As the IPR con-
tains elements related to incidence reduction as well as to extending survival, it conveys two
major aims of the programmatic response.
An IMR
The IMR (incidence:mortality ratio) is defined as the ratio of the number of people who
become HIV infected per year to the number of people among those already infected who die
(from any cause) per year. When this number is greater than one, the size of the population of
PLHIV grows; when it is less than one, the size of that population shrinks [21,22].
A target of IMR < 1 on its own does not require a reduction of mortality. In fact, dropping
below IMR < 1 is possible with a high level of mortality. An additional target therefore needs
to be considered in conjunction with the IMR target [21]. A possible target for a direct mortal-
ity reduction is that mortality among PLHIV should approach mortality among the HIV-nega-
tive population (which will be country and population specific). Indirect targets could relate to
ART coverage—for example, ART coverage> 70% [23] or ART coverage> 81% by 2020 and
>86% by 2030 [18,24].
There is a close relationship between the IPR (discussed above under the IPR section) and
the IMR. At equilibrium, the two metrics become equivalent if the IMR < 1 criterion provides
for the mortality rate being below the same level as that implied by the IPR threshold (1/D).
Measurement issues
Questions regarding measurement arise for each of the proposed metrics, as the availability of
empirical data is a challenge for all proposed metrics.
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Modelled estimates versus empirical estimates
There is a long history of countries developing modelled estimates of HIV incidence, HIV
prevalence, AIDS-related mortality, and all-cause mortality among PLHIV. A major process is
undertaken by UNAIDS and partners that involves soliciting expert advice about new model
features, software development, capacity building in modelling, and annual country-level
development of modelled estimates [25]. This results in the most widely available and consis-
tent set of country-level estimates and time trends in the incidence and prevalence of HIV and
HIV-related mortality. In addition, several academic groups are active in this field and publish
topic- or country-specific models and estimates [16,26,27] or global and country estimates
[28].
Clearly, the quality of modelled estimates depends on the availability and validity of input
data. Mathematical models that estimate HIV incidence and AIDS-related mortality may
include, besides demographic data and assumptions, the following empirical data: sentinel sur-
veillance prevalence among pregnant women, programmatic data on prevalence among preg-
nant women, national survey–derived HIV prevalence, numbers of people on ART, national
survey–derived incidence, cohort-derived incidence among 15–49 year olds, case reports of
new HIV diagnoses, case reports of AIDS-related deaths, and coverage and regimen distribu-
tion for prevention of mother-to-child transmission (PMTCT). Data-informed assumptions
are typically made about the survival probability of people receiving ART, the effectiveness of
antiretroviral regimens to prevent MTCT, and other parameters [29]. Modelled estimates are
typically produced at the national level and increasingly for subnational geographic entities:
however, currently they typically are not available for specific key population groups.
The major challenge with model-based estimates is that they tend to be most uncertain
(least precise) in recent years and are, by necessity, dependent on assumptions for which direct
empirical data are lacking. When comparing, for example, incidence and mortality, two quan-
tities are being compared, both of which are being modelled from a dataset that is predomi-
nantly informed by trends in HIV prevalence and ART coverage. This can be addressed by
using the models to ‘test’ whether there is evidence of a particular target being reached or not,
in which the uncertainty attendant in the methods is fully expressed. It may be the case that
with current surveillance systems and data availability, one may not be able to make very pre-
cise statements regarding meeting particular thresholds as soon as we would like. However,
new development in the availability of empirical data—especially measures of incidence and
deaths—will bolster this ability.
Empirical data on HIV incidence, AIDS-related mortality, all-cause
mortality among PLHIV, and HIV prevalence
Empirical data on HIV incidence are increasingly available but remain rare. Cohort studies
that measure the incidence rate directly are costly and time-consuming and may suffer from
participation bias [30]. Hence, only a few national cohort studies exist [31,32], with other stud-
ies focused on entire populations or subpopulations in specific locations [33,34]. Recently, the
cross-sectional population-based HIV impact assessment surveys [35] have been used to gen-
erate estimates of HIV incidence (using algorithms that include assays to estimate the number
of recent infections) at the national level, although not at the subnational level or among spe-
cific key populations. As are cohort studies, these surveys are also subject to participation bias.
Separate cross-sectional surveys among key populations are now also recommended to include
the measurement of incidence [36], although the body of empirical measurements is currently
limited. For both national surveys and surveys among key populations, having a sample size
that is large enough to estimate HIV incidence with precision is costly, and this will become
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even more so as the level of incidence falls to lower values in future years. Nevertheless, the
assay-based methods for the measurement of incidence in cross-sectional surveys continue to
be investigated and developed [37], and when this information is combined (in models) with
other data, the precision of model-based incidence estimates can be improved. Countries with
well-developed case-reporting systems can use the annual number of new diagnoses to esti-
mate HIV incidence taking into account other information on the time to diagnosis, underdi-
agnosis, and failure to report [38,39]. Efforts are ongoing in other countries (including those
with the highest levels of prevalence) to develop case-based surveillance and patient-monitor-
ing systems [40]—it is currently unclear whether such systems will allow for the estimation of
incidence among key populations.
Comprehensive empirical data on mortality among PLHIV are rare, especially in high-
prevalence countries. In countries with well-developed case-reporting systems, data are re-
corded on all deaths among PLHIV who are diagnosed. In these systems, a proportion of these
deaths are registered among people who were not previously known to be living with HIV.
Data on all-cause mortality among key populations living with HIV are not available for most
countries, although countries with well-developed case-reporting systems that include report-
ing of the assumed mode of transmission may be able to make estimates based on reported
data [39]. In countries with high prevalence of HIV and high mortality among PLHIV, the
overall level and the age- and sex-specific patterns of all-cause mortality may be used to con-
strain modelled estimates [41]. Comprehensive empirical data on AIDS-related mortality spe-
cifically are even rarer, especially in countries with a generalised epidemic. Failure to correctly
record AIDS-related deaths may be due to stigma [17,42]. In addition, registers may contain
the number of PLHIV who have died, but the vital status of individuals lost to follow-up may
not be up to date. In countries with well-developed vital registration systems, the failure to cor-
rectly record AIDS-related deaths may be due to misdiagnosis of the cause of death [43].
Empirical data on HIV prevalence are widely available. HIV prevalence data are generated
for key populations (typically only in specific locations) and for pregnant women in special
surveys or through routine reporting systems, especially in countries with a generalised epi-
demic, and for the entire population from national surveys such as the Demographic and
Health surveys [44] and, more recently, the population-based HIV impact assessments [35].
Conclusion
Much progress has been achieved in recent years in reducing HIV incidence and AIDS-related
deaths. In addition to the previously widely used metrics of incidence and mortality rates,
additional metrics that show percentage reductions or that relate the number of new infections
to either the total number of PLHIV or their all-cause mortality are useful to measure transi-
tions in national or local epidemics. These metrics are now increasingly being used, including
by UNAIDS and by the President’s Emergency Plan for AIDS Relief (PEPFAR) [2,3,23]. The
different metrics convey information about different aspects of the epidemic: metrics that
focus on incidence reductions centre on curbing epidemic spread such that reductions in sick-
ness, death, and fiscal burden will follow later; metrics that focus on reducing the death rate
speak to whether there is an immediate reduction in sickness and death; and the metrics that
relate to the size of the epidemic speak to whether the fiscal burden is immediately contracting
(IMR) or whether the response is ‘on track’ to reduce the fiscal burden (IPR)
The aim of the AIDS response in each local epidemic will be to reach the metric’s bench-
mark corresponding to epidemic transition and maintain the metric as low as possible below
this benchmark level. As the epidemic recedes, the response will need to adapt to the epidemic
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becoming concentrated in specific population groups, taking into account their specific social
and biological characteristics.
Progress in achieving HIV transitions is increasingly going to depend on effectively reduc-
ing stigma and discrimination, as they are a key determinant of effective service delivery.
Hence, specific tracking of progress in this area is required [2,3].
Given the importance of targets for accountability and programme management, and given
the dearth of empirical data, especially on HIV incidence and on mortality, more investment
in generating, compiling, reporting, and analysing empirical data is essential.
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